Where Generative AI Can Assist a Pharma Media Team
A value-risk matrix for generative AI in pharma media, separating assistive work like drafting and QA from consequential decisions that need tighter control.
The short answer
Generative AI can save a pharma media team real time. It can also produce confident errors, leak confidential data, and create compliance problems. The useful question is not whether to use it, but where the value is high and the risk manageable. A value-risk matrix helps prioritize.
Value and risk by use case
| Use case | Value | Risk | Notes |
|---|---|---|---|
| Summarizing public research and news | High | Low | Verify key facts against sources |
| Drafting briefs, agendas, and emails | High | Low to moderate | Keep confidential data out of unapproved tools |
| Creating QA checklists and templates | High | Low | Review for completeness |
| Explaining technical concepts to stakeholders | Moderate | Low | Check accuracy |
| Analyzing de-identified campaign data | High | Moderate | Verify calculations independently |
| Writing code for reports and dashboards | High | Moderate | Test outputs; review for data handling |
| Drafting promotional copy | Moderate | High | Full medical, legal, and regulatory review required |
| Generating media plans | Moderate | High | See evaluating AI-generated plans |
| Making automated bid or budget changes | Variable | High | See testing AI recommendations |
Start with assistive work
The best first uses are assistive: AI drafts or summarizes, and a person decides. These build familiarity with the tools' strengths and weaknesses at low risk.
- Meeting preparation. Summarize last quarter's reports into discussion points.
- Brief first drafts. Turn notes into a structured brief using a template like the programmatic brief.
- Checklist generation. Draft QA checklists, then have an expert refine them.
- Research summaries. Summarize public regulatory guidance, then verify against the source.
Be careful with numbers
Generative AI tools can make arithmetic and logic errors while sounding confident. For any analysis, verify calculations independently. Where possible, have the tool write code that performs calculations rather than doing them in text, and check the code.
Keep sensitive data out
Do not put identifiable health data, confidential client data, or non-public brand information into tools that are not approved for it. See using AI for campaign analysis without exposing sensitive data.
Promotional content needs full review
AI-drafted promotional content is still promotional content. It needs the same review as anything else, and reviewers should know AI was involved. Hallucinated claims or omitted risk information are serious problems. See human review for AI-assisted marketing.
Measure the value
Track time saved and error rates for AI-assisted tasks. If a use case saves little time or produces frequent errors, stop it.
Practical takeaway
Pick three low-risk, high-value use cases from the matrix. Pilot them for a month with approved tools, track time saved and errors found, and expand from there.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.